DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,663,587 B2 Hsieh Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,663,587 B2 Hsieh Et Al USOO9663587B2 (12) United States Patent (10) Patent No.: US 9,663,587 B2 Hsieh et al. (45) Date of Patent: May 30, 2017 (54) IL-17 BINDING PROTEINS 4,753,894 A 6, 1988 Frankel et al. 4,816,397 A 3, 1989 BOSS et al. 4,816,567 A 3/1989 Cabilly et al. (71) Applicant: AbbVie Inc., North Chicago, IL (US) 4,880,078 A 11/1989 Inoune et al. 4,943,533 A 7, 1990 Mendelsohn et al. (72) Inventors: Chung-Ming Hsieh, Newton, MA 4.946,778 A 8, 1990 Ladner et al. (US); Margaret Hugunin, North 4,980,286 A 12/1990 Morgan et al. Grafton, MA (US); Anwar Murtaza, 5,006,309 A 4, 1991 Khali1 et al. 5,063,081 A 11/1991 Cozzette et al. Westborough, MA (US); Bradford L. 5,089,424 A 2f1992 Khali1 et al. McRae, Northborough, MA (US); 5,128,326 A 7, 1992 Balazs et al. Yuliya Kutskova, Northborough, MA 5,135,875 A 8, 1992 Meucci et al. (US); John E. Memmott, Framingham, 5,223,409 A 6/1993 Ladner et al. MA (US); Jennifer M. Perez, 5,225,539 A 7, 1993 Winter 5,241,070 A 8, 1993 Law et al. Worcester, MA (US); Suju Zhong, 5,242,828 A 9/1993 Bergstrom et al. Shrewsbury, MA (US); Edit Tarcsa, 5,258.498 A 11/1993 Huston et al. Westborough, MA (US); Anca 5,290,540 A 3, 1994 Prince et al. Clabbers, Rutland, MA (US); Craig 5,294.404 A 3/1994 Grandone et al. Wallace, Sterling, MA (US); Shaughn 5,352,803 A 10/1994 Mattingly 5,359,093 A 10/1994 Adamczyk et al. H. Bryant, Worcester, MA (US); Mary 5,403.484 A 4/1995 Ladner et al. R. Leddy, North Attleboro, MA (US) 5,427,908 A 6/1995 Dower et al. 5,468,646 A 11/1995 Mattingly et al. (73) Assignee: ABBVIE INC., North Chicago, IL (US) 5,496.925 A 3/1996 Mattingly 5,500,362 A 3, 1996 Robinson et al. (*) Notice: Subject to any disclaimer, the term of this 5,516,637 A 5/1996 Huang et al. 5,530,101 A 6/1996 Queen et al. patent is extended or adjusted under 35 5,543,524 A 8/1996 Mattingly et al. U.S.C. 154(b) by 98 days. 5,558,864 A 9/1996 Bendig et al. 5,565,332 A 10/1996 Hoogenboom et al. (21) Appl. No.: 14/262,653 5,565,352 A 10, 1996 Hochstrasser et al. 5,571,698 A 11/1996 Ladner et al. (22) Filed: Apr. 25, 2014 5,573,904 A 11/1996 Mattingly (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2014/034.8856 A1 Nov. 27, 2014 CA 2 679 266 A1 9, 2008 Related U.S. Application Data EP O471293 A2 2, 1992 (62) Division of application No. 12/718,841, filed on Mar. (Continued) 5, 2010, now Pat. No. 8,835,610. (60) Provisional application No. 61/209.272, filed on Mar. OTHER PUBLICATIONS 5, 2009. Jonsson, et al., “Real-Time Biospecific Interaction Analysis Using Surface Plasmon Resonance and a Sensor Chip Technology.” (51) Int. Cl. Biotechniques, 11(5): 620-627 (1991). C07K I6/46 (2006.01) Jonsson et al., “Introducing a biosensor based technology for C07K 6/24 (2006.01) real-time biospecific interaction analysis.” Ann. Biol. Clin. 51: A 6LX 39/395 (2006.01) 19-26 (1993). A61 K 39/00 (2006.01) Jovanovic et al., “IL-17 stimulates the production and expression of proinflammatory cytokines, IL-13 and TNA-a, by human (52) U.S. Cl. macrophages,” J. Immunol. 160: 3513-3521 (1998). CPC ........ C07K 16/468 (2013.01); A61K 39/3955 Jungbluth et al., “A monoclonal antibody recognizing human can (2013.01); C07K 16/241 (2013.01); C07K cers with amplification/overexpression of the human epidermal I6/244 (2013.01); A61 K 2039/505 (2013.01); growth factor receptor.” Proc. Natl. Acad. Sci. USA, 100(2): 639 A6 IK 2039/507 (2013.01); A61 K 2300/00 644 (2003). (2013.01); C07K 231.6/96 (2013.01); C07K (Continued) 2317/21 (2013.01); C07K 23.17/31 (2013.01); C07K 2317/50 (2013.01); C07K 231 7/565 Primary Examiner — Brad Duffy (2013.01); C07K 2317/64 (2013.01); C07K Assistant Examiner — Nelson B Moseley, II 2317/76 (2013.01); C07K 2317/92 (2013.01) (74) Attorney, Agent, or Firm — Sterne, Kessler, (58) Field of Classification Search Goldstein and Fox P.L.L.C. None See application file for complete search history. (57) ABSTRACT Proteins that bind IL-17 and/or IL-17F are described along (56) References Cited with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for U.S. PATENT DOCUMENTS detecting IL-17 in cells, tissues, samples, and compositions. 4,526,938 A 7, 1985 Churchill et al. 4,554,101 A 11/1985 Hopp 45 Claims, No Drawings US 9,663,587 B2 Page 2 (56) References Cited 2005.0054078 A1 3, 2005 Miller et al. 2005, 0147610 A1 7/2005 Ghayur et al. U.S. PATENT DOCUMENTS 2006, OO18909 A1 1/2006 Oliner et al. 2006, O104968 A1 5, 2006 Bookbinder et al. 5,580,717 A 12/1996 Dower et al. 2006.0160164 A1 7/2006 Miller et al. 2007/OOO3567 A1 1/2007 Paterson et al. 3. A leg R3s, al. 2007, 0071675 A1 3, 2007 Wu et al. 5,624,821 A 4/1997 Winter et al. 2007/O160576 A1 7/2007 Arnott et al. 5,627,052 A 5, 1997 Schrader et al. 2007/0196371 A1 8, 2007 Kuestner et al. 5,641,870 A 6/1997 Rinderknecht et al. 2008.0020401 A1 1/2008 Grenier et al. 5,648,260 A 7, 1997 Winter et al. 2008/0219971 A1 9, 2008 Smith et al. 2008/0248493 A1 10/2008 Mattingly et al. 3597; A 88: Railal. 2008/0269.467 A1 10, 2008 Alan et al. 5,679,377 A 10, 1997 Bernstein et al. 2010.0099.103 A1 4, 2010 Hsieh et al. 5,693,762 A 12/1997 Queen et al. 2010.0167301 A1 7/2010 Collier et al. 5,698,426 A 12/1997 Huse et al. 2012.0034160 A1 2, 2012 Ghayur et al. 5,714,350 A 2f1998 CO et al. 2014/0335564 A1 11/2014 Hsieh 5,714,352 A 2f1998 Jakobovits et al. 2014/0343267 A1 11/2014 Hsieh 5,723,323 A 3, 1998 Kauffman et al. 2014/0348834 A1 11/2014 Hsieh 5,733,743 A 3, 1998 Johnson et al. 2014,034.8856 A1 11/2014 Hsieh 5,736,137 A 4, 1998 Anderson et al. 2014/0356909 A1 12/2014 Hsieh 5,750,753 A 5, 1998 Kimae et al. 5,763,192 A 6/1998 Kauffman et al. FOREIGN PATENT DOCUMENTS 5,766,886 A 6, 1998 Studnicka et al. 5,780,225 A 7/1998 Wigler et al. 5,783,699 A 7/1998 Mattingly et al. E. 83.88 E. 5,814,476 A 9, 1998 Kauffman et al. EP O519596 B1 2, 2005 5,824,514 A 10, 1998 Kauffman et al. WO WO9005144 A1 5, 1990 5,891,996 A 4, 1999 Mateo de Acosta del Rio et al. WO WO9014443 11, 1990 5,912,015 A 6, 1999 Bernstein et al. WO WO9105548 5, 1991 5,934.272 A 8/1999 Lloyd et al. WO WO9110741 7, 1991 5,976,862 A 11/1999 Kauffman et al. WO WO92O2551 2, 1992 5,985,615. A 1 1/1999 Jakobovits et al. WO WO9211272 7, 1992 5,989.463 A 1 1/1999 Tracy et al. WO WO9215679 9, 1992 6,066,719 A 5/2000 Zapata WO WO922O791 11, 1992 6,114,598 A 9/2000 Kucherlapati et al. WO WO9306213 A1 4f1993 6,130,364. A 10/2000 Jakobovits et al. WO WO9311236 6, 1993 6,204,023 B1 3, 2001 Robinson et al. WO WO9418219 8, 1994 6.214.984 B1 4/2001 Zapata WO WO9515982 6, 1995 6,258,562 B1 7/2001 Salfeld et al. WO WO962O698 T 1996 6,506,883 B2 1/2003 Meteo de Acosta del Rio et al. WO WO964O210 12/1996 6,660,843 B1 12/2003 Feige et al. WO WO972OO32 6, 1997 6,914,128 B1 7/2005 Salfeld et al. WO WO9732572 9, 1997 7,247,301 B2 7/2007 van de Winkel et al. WO WO9744O13 11, 1997 7,838,638 B2 11/2010 Allan et al. WO WO9824893 6, 1998 2002/0137134 A1 9/2002 Gerngross WO WO985O433 11, 1998 2003/009 1561 A1 5/2003 van de Winkel et al. WO WO991.5154 4f1999 2003/0170881 A1 9, 2003 Davis et al. WO WO992O253 4f1999 2003. O1863.74 A1 10, 2003 Hufton et al. WO WO992SO44 5, 1999 2003/0219438 A1 11, 2003 Salfeld et al. WO WO994.5031 9, 1999 2004/OO18577 A1 1/2004 Campbell et al. WO WO995.1773 10, 1999 2004, OO18590 A1 1/2004 Gerngross WO WO9953049 10, 1999 2005, OO42664 A1 2, 2005 Wu et al. WO WO99.54342 10, 1999 US 9,663,587 B2 Page 3 (56) References Cited Kipriyanov et al., “Single-chain antibody streptavidin fusions: Tetrameric bifunctional scFv-complexes with biotin binding activ FOREIGN PATENT DOCUMENTS ity and enhanced affinity to antigen.” Hum. Antibod. Hybridomas, 6:93-101 (1995). WO WO9966903 12/1999 WO WOOOO9560 2, 2000 Kirkham et al., “Synovial membrane cytokine expression is pre WO WOOO34337 6, 2000 dictive of joint damage progression in rheumatoid arthritis.” Arthri WO WOOO37.504 6, 2000 tis Rheum.
Load more

Recommended publications
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • WO 2012/144892 Al 26 October 2012 (26.10.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/144892 Al 26 October 2012 (26.10.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/192 (2006.01) A61P 9/10 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/352 (2006.01) A61P 31/04 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61P 3/10 (2006.01) A61K 133/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (21) Number: International Application HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, PCT/NL20 12/050241 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 12 April 2012 (12.04.2012) OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (25) Filing Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 2006621 18 April 201 1 (18.04.201 1) NL GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, (71) Applicant (for all designated States except US): TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, FYTAGORAS B.V.
    [Show full text]
  • BMS's Alternatives to Imclone
    October 07, 2008 BMS's alternatives to ImClone Evaluate Vantage Bristol-Myers Squibb’s failure to acquire ImClone, a deal which the pharma giant claimed to be “a strategically and financially sound add-on”, throws open the question as to whether BMS remains committed to an oncology-based biotech acquisition to bolster its pipeline. Assuming BMS keeps faith with this strategy, yesterday’s official statement referred to “other alternatives open to the company” as part of the reason to abort the ImClone deal, an analysis of peer group data from EvaluatePharma reveals a handful of companies that may provide a suitable alternative for BMS, including Alexion Pharmaceuticals, PDL BioPharma and Medarex. Flush with cash Including the $1bn BMS will receive when Eli Lilly completes its acquisition of ImClone, the group is expected to hold around $9.4bn in cash by the end of the year. In this context, all the following companies are comfortably within BMS’s purchasing power, especially in light of the recent declines for most biotech stocks. This analysis includes companies with an attractive monoclonal antibody platform technology, antibody candidates in mid-to-late stage clinical trials to treat various cancers, and ones that also still have a market capitalisation greater than $500m. YTD 2014 Market Enterprise share Pharma Current sales / Cap. Value Lead antibody Partner? price class status royalty ($m) ($m) change ($m) Anti- Alexion 3,010 3,109 3.13% ALXN6000 CD200 Phase II - no Pharmaceuticals MAb Anti- United 2,164 2,199 (2.88%) 3F8 MAb GD2
    [Show full text]
  • Pdl Biopharma 2005 Annual Report 1
    In 2005, we achieved our commercial transformation. Looking ahead, our vision is 2010. 2005 Annual Report 2 LETTER TO SHAREHOLDERS 6 OUR PRODUCTS 14 OUR PIPELINE 20 OUR PERFORMANCE 24 OUR MANAGEMENT 25 FINANCIAL REPORT 102 CORPORATE INFORMATION 104 CODE OF CONDUCT A clear vision: from Through strategic acquisitions and partnerships, we have become a commercial biopharmaceutical company, reflected in our new name, PDL BioPharma. We have a portfolio of acute-care hospital products being commercialized by our own U.S. marketing and sales force. We have a growing and diverse revenue base, six promising product candidates in clinical development and a strategy to fuel our pipeline through internal discovery and collaboration. PDL BIOPHARMA 2005 ANNUAL REPORT 1 ◆ We hit our goal in 2005 to create a commercial business, while enhancing shareholder value. We’ve transformed our business and now we’re focused on becoming a sustainable and growing biopharmaceutical company. 2005 to Vision 2010 We have set our sights even higher over the next five years and as part of our Vision 2010 aims, we are executing the strategies that will enable us to solidify our position as a top-tier biopharmaceutical company. STRATEGY 1 ◆ Reach or maintain No. 1 or No. 2 dollar market shares for marketed drugs STRATEGY 2 ◆ Develop and launch at least three products STRATEGY 3 ◆ Establish a deeper, stronger pipeline STRATEGY 4 ◆ Expand commercial operations to Europe STRATEGY 5 ◆ Sustainably grow revenue and earnings performance 2 LETTER TO SHAREHOLDERS To Our Shareholders… MARK McDADE CHIEF EXECUTIVE OFFICER 2005 was a year of dramatic change.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • Understanding History, and Not Repeating It. Neuroprotection For
    Clinical Neurology and Neurosurgery 129 (2015) 1–9 Contents lists available at ScienceDirect Clinical Neurology and Neurosurgery jo urnal homepage: www.elsevier.com/locate/clineuro Review Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: From review to preview a a b b,c a,b,c,d,∗ Stephen Grupke , Jason Hall , Michael Dobbs , Gregory J. Bix , Justin F. Fraser a Department of Neurosurgery, University of Kentucky, Lexington, USA b Department of Neurology, University of Kentucky, Lexington, USA c Department of Anatomy and Neurobiology, University of Kentucky, Lexington, USA d Department of Radiology, University of Kentucky, Lexington, USA a r t i c l e i n f o a b s t r a c t Article history: Background: Neuroprotection for ischemic stroke is a growing field, built upon the elucidation of the Received 17 April 2014 biochemical pathways of ischemia first studied in the 1970s. Beginning in the early 1990s, means by Received in revised form 7 November 2014 which to pharmacologically intervene and counteract these pathways have been sought, though with Accepted 13 November 2014 little clinical success. Through a comprehensive review of translations from laboratory to clinic, we aim Available online 3 December 2014 to evaluate individual mechanisms of action, while highlighting potential barriers to success that will guide future research. Keywords: Methods: The MEDLINE database and The Internet Stroke Center clinical trials registry were queried Acute stroke Angiography for trials involving the use of neuroprotective agents in acute ischemic stroke in human subjects. For the purpose of the review, neuroprotective agents refer to medications used to preserve or protect the Brain ischemia Drug trials potentially ischemic tissue after an acute stroke, excluding treatments designed to re-establish perfusion.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,258.268 B2 Wu Et Al
    USOO8258268B2 (12) United States Patent (10) Patent No.: US 8,258.268 B2 Wu et al. (45) Date of Patent: Sep. 4, 2012 (54) DUAL VARIABLE DOMAIN 5,624,821 A 4/1997 Winter et al. MMUNOGLOBULIN AND USES THEREOF 5,627,052 A 5/1997 Schrader et al. 5,641,870 A 6/1997 Rinderknecht et al. 5,648,260 A 7, 1997 Winter et al. (75) Inventors: Chengbin Wu, Shrewsbury, MA (US); 5,658,727 A 8, 1997 Barbas et al. Tariq Ghayur, Holliston, MA (US); 5,677,171 A 10, 1997 Hudziak et al. 5,679,377 A 10, 1997 Bernstein et al. Richard W. Dixon, Jefferson, MA (US); 5,693,762 A 12/1997 Queen et al. Jochen G. Salfeld, North Grafton, MA 5,698,426 A 12/1997 Huse et al. (US) 5,714,350 A 2f1998 CO et al. 5,714,352 A 2f1998 Jakobovits (73) Assignee: Abbott Laboratories, Abbott Park, IL 5,723,323 A 3, 1998 Kauffman et al. 5,733,743 A 3, 1998 Johnson et al. (US) 5,736,137 A 4, 1998 Anderson et al. 5,750,753 A 5/1998 Kimae et al. (*) Notice: Subject to any disclaimer, the term of this 5,763,192 A 6/1998 Kauffman et al. patent is extended or adjusted under 35 5,766,886 A 6/1998 Studnicka et al. 5,780,225 A 7/1998 Wigler et al. U.S.C. 154(b) by 0 days. 5,814,476 A 9, 1998 Kauffman et al. 5,817483. A 10, 1998 Kauffman et al.
    [Show full text]
  • Ep 3178848 A1
    (19) TZZ¥__T (11) EP 3 178 848 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 14.06.2017 Bulletin 2017/24 C07K 16/28 (2006.01) A61K 39/395 (2006.01) C07K 16/30 (2006.01) (21) Application number: 15198715.3 (22) Date of filing: 09.12.2015 (84) Designated Contracting States: (72) Inventor: The designation of the inventor has not AL AT BE BG CH CY CZ DE DK EE ES FI FR GB yet been filed GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Cueni, Leah Noëmi et al Designated Extension States: F. Hoffmann-La Roche AG BA ME Patent Department Designated Validation States: Grenzacherstrasse 124 MA MD 4070 Basel (CH) (71) Applicant: F. Hoffmann-La Roche AG 4070 Basel (CH) (54) TYPE II ANTI-CD20 ANTIBODY FOR REDUCING FORMATION OF ANTI-DRUG ANTIBODIES (57) The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent comprising administration of a Type II anti-CD20 antibody, e.g. obinutuzumab, to the subject prior to administration of the therapeutic agent. EP 3 178 848 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 178 848 A1 Description Field of the Invention 5 [0001] The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent.
    [Show full text]
  • I Regulations
    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
    [Show full text]
  • Integrins As Therapeutic Targets: Successes and Cancers
    cancers Review Integrins as Therapeutic Targets: Successes and Cancers Sabine Raab-Westphal 1, John F. Marshall 2 and Simon L. Goodman 3,* 1 Translational In Vivo Pharmacology, Translational Innovation Platform Oncology, Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany; sabine.raab@merckgroup.com 2 Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK; j.f.Marshall@qmul.ac.uk 3 Translational and Biomarkers Research, Translational Innovation Platform Oncology, Merck KGaA, 64293 Darmstadt, Germany * Correspondence: simgoo@gmx.net; Tel.: +49-6155-831931 Academic Editor: Helen M. Sheldrake Received: 22 July 2017; Accepted: 14 August 2017; Published: 23 August 2017 Abstract: Integrins are transmembrane receptors that are central to the biology of many human pathologies. Classically mediating cell-extracellular matrix and cell-cell interaction, and with an emerging role as local activators of TGFβ, they influence cancer, fibrosis, thrombosis and inflammation. Their ligand binding and some regulatory sites are extracellular and sensitive to pharmacological intervention, as proven by the clinical success of seven drugs targeting them. The six drugs on the market in 2016 generated revenues of some US$3.5 billion, mainly from inhibitors of α4-series integrins. In this review we examine the current developments in integrin therapeutics, especially in cancer, and comment on the health economic implications of these developments. Keywords: integrin; therapy; clinical trial; efficacy; health care economics 1. Introduction Integrins are heterodimeric cell-surface adhesion molecules found on all nucleated cells. They integrate processes in the intracellular compartment with the extracellular environment. The 18 α- and 8 β-subunits form 24 different heterodimers each having functional and tissue specificity (reviewed in [1,2]).
    [Show full text]
  • INN Working Document 05.179 Update 2011
    INN Working Document 05.179 Update 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]